| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| CD8-Positive T-Lymphocytes | 22 | 2018 | 266 | 3.210 |
Why?
|
| Cyclophosphamide | 8 | 2016 | 129 | 2.370 |
Why?
|
| Dendritic Cells | 13 | 2017 | 201 | 2.200 |
Why?
|
| Cancer Vaccines | 12 | 2017 | 61 | 2.070 |
Why?
|
| Adoptive Transfer | 15 | 2018 | 100 | 1.770 |
Why?
|
| Pancreatic Neoplasms | 14 | 2017 | 332 | 1.730 |
Why?
|
| Melanoma | 15 | 2016 | 335 | 1.710 |
Why?
|
| Interleukin-12 | 8 | 2015 | 75 | 1.540 |
Why?
|
| Receptors, Antigen, T-Cell | 10 | 2019 | 135 | 1.520 |
Why?
|
| Breast Neoplasms | 23 | 2021 | 1536 | 1.410 |
Why?
|
| Poly I-C | 5 | 2017 | 20 | 1.320 |
Why?
|
| Antigens, Neoplasm | 13 | 2019 | 132 | 1.260 |
Why?
|
| T-Lymphocytes | 8 | 2019 | 597 | 1.250 |
Why?
|
| Immunotherapy, Adoptive | 11 | 2019 | 132 | 1.120 |
Why?
|
| Lymph Nodes | 16 | 2012 | 258 | 1.030 |
Why?
|
| Mice, Inbred C57BL | 29 | 2018 | 2791 | 0.960 |
Why?
|
| Lymphocyte Activation | 12 | 2018 | 397 | 0.950 |
Why?
|
| Interleukin-15 | 7 | 2018 | 66 | 0.910 |
Why?
|
| Neoplasms | 11 | 2019 | 1667 | 0.890 |
Why?
|
| T-Lymphocyte Subsets | 8 | 2015 | 126 | 0.890 |
Why?
|
| Mice | 43 | 2018 | 8474 | 0.890 |
Why?
|
| Adenocarcinoma | 9 | 2014 | 475 | 0.860 |
Why?
|
| Myeloid Cells | 4 | 2013 | 57 | 0.840 |
Why?
|
| Vaccination | 8 | 2017 | 189 | 0.830 |
Why?
|
| Adjuvants, Immunologic | 5 | 2006 | 63 | 0.830 |
Why?
|
| Neoplasm Proteins | 7 | 2008 | 307 | 0.780 |
Why?
|
| Immunotherapy | 6 | 2019 | 215 | 0.780 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2015 | 411 | 0.780 |
Why?
|
| Toll-Like Receptor 3 | 5 | 2009 | 13 | 0.770 |
Why?
|
| Animals | 57 | 2018 | 20881 | 0.760 |
Why?
|
| Melanoma, Experimental | 8 | 2017 | 95 | 0.730 |
Why?
|
| General Surgery | 2 | 2016 | 95 | 0.710 |
Why?
|
| RNA, Antisense | 4 | 2005 | 25 | 0.680 |
Why?
|
| Genetic Therapy | 6 | 2015 | 291 | 0.680 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2016 | 74 | 0.640 |
Why?
|
| Biomarkers, Tumor | 12 | 2010 | 508 | 0.640 |
Why?
|
| Lymphatic Metastasis | 16 | 2013 | 274 | 0.630 |
Why?
|
| Skin Neoplasms | 5 | 2015 | 375 | 0.620 |
Why?
|
| Mice, Transgenic | 16 | 2016 | 1033 | 0.610 |
Why?
|
| Interleukin-2 | 5 | 2018 | 133 | 0.610 |
Why?
|
| Lymphocyte Depletion | 4 | 2018 | 34 | 0.600 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 7 | 2016 | 91 | 0.580 |
Why?
|
| Polylysine | 1 | 2017 | 13 | 0.580 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2017 | 7 | 0.580 |
Why?
|
| Spleen | 7 | 2012 | 301 | 0.570 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2021 | 33 | 0.550 |
Why?
|
| Cell Line, Tumor | 17 | 2018 | 1851 | 0.530 |
Why?
|
| Congresses as Topic | 1 | 2016 | 85 | 0.530 |
Why?
|
| Neutrophils | 1 | 2016 | 204 | 0.510 |
Why?
|
| Automobile Driving | 2 | 2016 | 88 | 0.500 |
Why?
|
| Surgical Procedures, Operative | 2 | 2018 | 124 | 0.490 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 148 | 0.480 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 268 | 0.480 |
Why?
|
| Humans | 88 | 2021 | 68618 | 0.480 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 18 | 2012 | 710 | 0.470 |
Why?
|
| Acetylglucosamine | 5 | 2010 | 46 | 0.470 |
Why?
|
| Peptide Fragments | 6 | 2004 | 483 | 0.460 |
Why?
|
| Interleukin-15 Receptor alpha Subunit | 2 | 2016 | 10 | 0.450 |
Why?
|
| Brachytherapy | 4 | 2009 | 79 | 0.450 |
Why?
|
| Female | 56 | 2021 | 38074 | 0.430 |
Why?
|
| Antigen Presentation | 3 | 2009 | 76 | 0.420 |
Why?
|
| RNA, Messenger | 10 | 2010 | 1664 | 0.420 |
Why?
|
| Transduction, Genetic | 4 | 2015 | 81 | 0.420 |
Why?
|
| Transplantation Conditioning | 2 | 2009 | 34 | 0.410 |
Why?
|
| Genetic Vectors | 6 | 2008 | 312 | 0.410 |
Why?
|
| Bone Marrow | 2 | 2012 | 168 | 0.400 |
Why?
|
| Bone Marrow Cells | 2 | 2009 | 217 | 0.400 |
Why?
|
| Immunosuppressive Agents | 3 | 2012 | 514 | 0.380 |
Why?
|
| Uteroglobin | 2 | 2008 | 5 | 0.380 |
Why?
|
| Cell Proliferation | 3 | 2017 | 1174 | 0.370 |
Why?
|
| Hypothermia | 1 | 2011 | 37 | 0.370 |
Why?
|
| Surgery Department, Hospital | 1 | 2010 | 19 | 0.360 |
Why?
|
| Polymerase Chain Reaction | 4 | 2000 | 492 | 0.360 |
Why?
|
| Glutathione Transferase | 9 | 2003 | 166 | 0.360 |
Why?
|
| Linear Models | 1 | 2012 | 521 | 0.360 |
Why?
|
| Lymph Node Excision | 5 | 2013 | 91 | 0.350 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 329 | 0.350 |
Why?
|
| Interferon Type I | 2 | 2007 | 32 | 0.350 |
Why?
|
| Mastectomy, Segmental | 7 | 2021 | 64 | 0.350 |
Why?
|
| Vaccines, Subunit | 2 | 2007 | 10 | 0.350 |
Why?
|
| Paclitaxel | 3 | 2015 | 140 | 0.340 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 57 | 0.340 |
Why?
|
| Neoplasm Metastasis | 7 | 2013 | 306 | 0.340 |
Why?
|
| Flow Cytometry | 10 | 2016 | 489 | 0.340 |
Why?
|
| Disease Models, Animal | 8 | 2016 | 2550 | 0.340 |
Why?
|
| Prognosis | 14 | 2021 | 2093 | 0.330 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2016 | 79 | 0.320 |
Why?
|
| Retroviridae | 1 | 2008 | 29 | 0.320 |
Why?
|
| Neoplasm Staging | 14 | 2016 | 800 | 0.320 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2013 | 101 | 0.320 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 281 | 0.310 |
Why?
|
| Epitopes | 3 | 1999 | 146 | 0.310 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2003 | 29 | 0.310 |
Why?
|
| Molecular Sequence Data | 16 | 2003 | 1447 | 0.300 |
Why?
|
| Aged | 26 | 2017 | 14862 | 0.300 |
Why?
|
| Gene Transfer Techniques | 2 | 2013 | 173 | 0.290 |
Why?
|
| Down-Regulation | 1 | 2008 | 447 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 4 | 2013 | 369 | 0.270 |
Why?
|
| Liver Neoplasms | 4 | 2016 | 334 | 0.270 |
Why?
|
| Interleukin-7 | 2 | 2017 | 18 | 0.270 |
Why?
|
| Carcinoembryonic Antigen | 3 | 2013 | 17 | 0.270 |
Why?
|
| Triticum | 5 | 2003 | 14 | 0.270 |
Why?
|
| Middle Aged | 28 | 2020 | 21147 | 0.270 |
Why?
|
| Membrane Glycoproteins | 5 | 2013 | 370 | 0.270 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2021 | 62 | 0.260 |
Why?
|
| Bystander Effect | 1 | 2005 | 10 | 0.260 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 94 | 0.260 |
Why?
|
| Membrane Proteins | 1 | 2010 | 617 | 0.260 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2016 | 66 | 0.250 |
Why?
|
| Cytokines | 3 | 2016 | 866 | 0.250 |
Why?
|
| Immunologic Memory | 5 | 2016 | 75 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2016 | 756 | 0.240 |
Why?
|
| RNA, Small Interfering | 4 | 2015 | 434 | 0.240 |
Why?
|
| RNA-Binding Proteins | 5 | 2008 | 215 | 0.240 |
Why?
|
| Adult | 26 | 2015 | 21403 | 0.240 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 88 | 0.240 |
Why?
|
| Thymoma | 3 | 2003 | 14 | 0.240 |
Why?
|
| Sarcoma | 3 | 2013 | 70 | 0.240 |
Why?
|
| Amino Acid Sequence | 13 | 2003 | 1083 | 0.230 |
Why?
|
| Hemostatics | 2 | 2004 | 47 | 0.230 |
Why?
|
| Thymus Neoplasms | 2 | 2003 | 17 | 0.220 |
Why?
|
| Mice, Knockout | 5 | 2016 | 1692 | 0.220 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2003 | 47 | 0.220 |
Why?
|
| Rectal Neoplasms | 2 | 2015 | 75 | 0.220 |
Why?
|
| Aged, 80 and over | 13 | 2015 | 4848 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 3 | 2010 | 532 | 0.220 |
Why?
|
| Immunotherapy, Active | 2 | 2017 | 6 | 0.210 |
Why?
|
| Cells, Cultured | 7 | 2016 | 2673 | 0.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2012 | 53 | 0.210 |
Why?
|
| Peptides | 4 | 2017 | 455 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 8 | 2003 | 852 | 0.210 |
Why?
|
| Lung Neoplasms | 5 | 2008 | 1173 | 0.210 |
Why?
|
| Zea mays | 6 | 2003 | 27 | 0.210 |
Why?
|
| Herbicides | 8 | 2003 | 24 | 0.210 |
Why?
|
| Arabidopsis | 4 | 2003 | 20 | 0.210 |
Why?
|
| Vaccines, Synthetic | 2 | 2006 | 19 | 0.210 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2002 | 64 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2008 | 300 | 0.200 |
Why?
|
| Internship and Residency | 2 | 2010 | 596 | 0.200 |
Why?
|
| Male | 27 | 2018 | 37321 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 468 | 0.190 |
Why?
|
| Moloney murine leukemia virus | 2 | 2015 | 13 | 0.180 |
Why?
|
| Surgical Wound Infection | 3 | 2011 | 168 | 0.180 |
Why?
|
| Polysaccharides | 2 | 1999 | 176 | 0.180 |
Why?
|
| Poaceae | 4 | 2003 | 12 | 0.180 |
Why?
|
| Tumor Burden | 4 | 2016 | 132 | 0.180 |
Why?
|
| Oncogenes | 1 | 2000 | 71 | 0.180 |
Why?
|
| RNA, Neoplasm | 4 | 2015 | 76 | 0.180 |
Why?
|
| Adenoviridae | 4 | 2005 | 295 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 446 | 0.170 |
Why?
|
| Apoptosis | 5 | 2017 | 1641 | 0.170 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 135 | 0.160 |
Why?
|
| Biopsy | 2 | 1998 | 540 | 0.160 |
Why?
|
| Macrophage Activation | 1 | 1999 | 75 | 0.160 |
Why?
|
| Cell Survival | 3 | 2012 | 901 | 0.160 |
Why?
|
| Axilla | 4 | 2010 | 36 | 0.160 |
Why?
|
| Clinical Protocols | 2 | 2016 | 172 | 0.160 |
Why?
|
| Mice, SCID | 4 | 2010 | 238 | 0.160 |
Why?
|
| Neoplasms, Experimental | 2 | 2012 | 118 | 0.160 |
Why?
|
| Deoxycytidine | 3 | 2014 | 83 | 0.160 |
Why?
|
| CD11b Antigen | 2 | 2010 | 47 | 0.160 |
Why?
|
| Goiter, Substernal | 1 | 1998 | 1 | 0.160 |
Why?
|
| Goiter, Nodular | 1 | 1998 | 2 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2018 | 199 | 0.160 |
Why?
|
| Mediastinal Diseases | 1 | 1998 | 15 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 214 | 0.160 |
Why?
|
| HLA-B27 Antigen | 1 | 2018 | 4 | 0.160 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 5 | 0.160 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 5 | 0.160 |
Why?
|
| Immunodominant Epitopes | 1 | 2018 | 13 | 0.150 |
Why?
|
| Choristoma | 1 | 1998 | 20 | 0.150 |
Why?
|
| Prospective Studies | 8 | 2010 | 3705 | 0.150 |
Why?
|
| Quality Improvement | 2 | 2020 | 413 | 0.150 |
Why?
|
| Thyroid Gland | 1 | 1998 | 67 | 0.150 |
Why?
|
| Macrophage Colony-Stimulating Factor | 2 | 1996 | 26 | 0.150 |
Why?
|
| Colonic Neoplasms | 2 | 2008 | 299 | 0.150 |
Why?
|
| Breast Diseases | 1 | 1997 | 40 | 0.150 |
Why?
|
| Pilot Projects | 3 | 2017 | 1342 | 0.150 |
Why?
|
| Treatment Outcome | 7 | 2018 | 7029 | 0.150 |
Why?
|
| Peritoneal Neoplasms | 2 | 2015 | 23 | 0.150 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2017 | 7 | 0.150 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 53 | 0.140 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2007 | 38 | 0.140 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 145 | 0.140 |
Why?
|
| Base Sequence | 5 | 2001 | 1015 | 0.140 |
Why?
|
| Breast | 1 | 1997 | 137 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 1996 | 17 | 0.140 |
Why?
|
| Acetyl-CoA Carboxylase | 4 | 2003 | 5 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2016 | 29 | 0.140 |
Why?
|
| Guanine Nucleotides | 1 | 2016 | 12 | 0.140 |
Why?
|
| Cybernetics | 2 | 2016 | 2 | 0.140 |
Why?
|
| Kinetics | 6 | 2012 | 1047 | 0.140 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2016 | 12 | 0.140 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2016 | 16 | 0.140 |
Why?
|
| Opioid-Related Disorders | 1 | 2020 | 298 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1996 | 40 | 0.130 |
Why?
|
| Drug Therapy | 1 | 2016 | 71 | 0.130 |
Why?
|
| Cohort Studies | 5 | 2010 | 2358 | 0.130 |
Why?
|
| Xenobiotics | 4 | 2003 | 17 | 0.130 |
Why?
|
| Th17 Cells | 1 | 2017 | 116 | 0.130 |
Why?
|
| Pyrroles | 1 | 2016 | 83 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 77 | 0.130 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 32 | 0.130 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2015 | 6 | 0.130 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2015 | 9 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2008 | 235 | 0.130 |
Why?
|
| Cell Division | 6 | 2011 | 541 | 0.130 |
Why?
|
| Indoles | 1 | 2016 | 146 | 0.130 |
Why?
|
| Immunohistochemistry | 4 | 2004 | 1174 | 0.130 |
Why?
|
| Southeastern United States | 1 | 2016 | 281 | 0.130 |
Why?
|
| Colostomy | 1 | 2015 | 15 | 0.130 |
Why?
|
| Ileostomy | 1 | 2015 | 14 | 0.130 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2015 | 8 | 0.130 |
Why?
|
| Vaccinia virus | 1 | 1996 | 97 | 0.130 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2019 | 16 | 0.130 |
Why?
|
| Granzymes | 1 | 2015 | 19 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 498 | 0.130 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2015 | 9 | 0.130 |
Why?
|
| Immunoglobulin Joining Region | 1 | 1994 | 3 | 0.120 |
Why?
|
| Colorectal Neoplasms | 2 | 2013 | 561 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 3 | 2013 | 511 | 0.120 |
Why?
|
| Neoplasm Transplantation | 5 | 2013 | 160 | 0.120 |
Why?
|
| Cloning, Molecular | 9 | 2003 | 357 | 0.120 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1994 | 40 | 0.120 |
Why?
|
| Retrospective Studies | 8 | 2021 | 7277 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 231 | 0.120 |
Why?
|
| Glucosyltransferases | 3 | 2003 | 28 | 0.120 |
Why?
|
| Regression Analysis | 4 | 2010 | 737 | 0.120 |
Why?
|
| Suramin | 1 | 1994 | 9 | 0.120 |
Why?
|
| Brain Edema | 2 | 1991 | 50 | 0.120 |
Why?
|
| Vaccines, DNA | 2 | 2012 | 9 | 0.120 |
Why?
|
| Receptors, Interleukin-12 | 2 | 2012 | 4 | 0.120 |
Why?
|
| Interferon-gamma | 3 | 2012 | 241 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 163 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 30 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2016 | 211 | 0.120 |
Why?
|
| Gene Expression Profiling | 3 | 2005 | 498 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 54 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 39 | 0.110 |
Why?
|
| Mucin-1 | 1 | 2013 | 35 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2013 | 26 | 0.110 |
Why?
|
| Verapamil | 1 | 1993 | 30 | 0.110 |
Why?
|
| Dizocilpine Maleate | 1 | 1993 | 43 | 0.110 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 1465 | 0.110 |
Why?
|
| Immunization | 1 | 2013 | 86 | 0.110 |
Why?
|
| Ovalbumin | 3 | 2004 | 33 | 0.110 |
Why?
|
| Extremities | 1 | 2013 | 49 | 0.110 |
Why?
|
| Aniline Compounds | 2 | 2003 | 52 | 0.110 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2013 | 28 | 0.110 |
Why?
|
| Hypothermia, Induced | 2 | 2004 | 93 | 0.110 |
Why?
|
| Drug Carriers | 1 | 2014 | 90 | 0.110 |
Why?
|
| Receptors, Transferrin | 1 | 2013 | 18 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 320 | 0.110 |
Why?
|
| Genes, p53 | 1 | 2013 | 41 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 149 | 0.110 |
Why?
|
| Calcium Channel Blockers | 1 | 1993 | 138 | 0.110 |
Why?
|
| Isoenzymes | 6 | 2003 | 308 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 7 | 2003 | 231 | 0.110 |
Why?
|
| Sensitivity and Specificity | 8 | 2006 | 1753 | 0.100 |
Why?
|
| Ear, External | 1 | 1992 | 14 | 0.100 |
Why?
|
| DNA Primers | 2 | 2004 | 302 | 0.100 |
Why?
|
| Ear Neoplasms | 1 | 1992 | 13 | 0.100 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Body Temperature | 2 | 2010 | 116 | 0.100 |
Why?
|
| Halothane | 1 | 1992 | 5 | 0.100 |
Why?
|
| Hemostatic Techniques | 2 | 2004 | 23 | 0.100 |
Why?
|
| Isoflurane | 1 | 1992 | 16 | 0.100 |
Why?
|
| Toll-Like Receptors | 2 | 2009 | 56 | 0.100 |
Why?
|
| Glutathione | 4 | 2003 | 343 | 0.100 |
Why?
|
| Ischemia | 1 | 1993 | 229 | 0.100 |
Why?
|
| Immunocompetence | 1 | 2011 | 19 | 0.100 |
Why?
|
| Recombinant Proteins | 6 | 2003 | 742 | 0.100 |
Why?
|
| Lipid Metabolism | 3 | 2003 | 186 | 0.100 |
Why?
|
| Behavior | 1 | 2012 | 59 | 0.100 |
Why?
|
| Hepatectomy | 1 | 1992 | 58 | 0.100 |
Why?
|
| Disease-Free Survival | 5 | 2013 | 349 | 0.100 |
Why?
|
| Time Factors | 3 | 2006 | 4655 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2012 | 118 | 0.100 |
Why?
|
| Cell Differentiation | 4 | 2015 | 1034 | 0.090 |
Why?
|
| Transcription Factors | 4 | 2015 | 753 | 0.090 |
Why?
|
| Body Temperature Regulation | 1 | 2011 | 29 | 0.090 |
Why?
|
| Mammaglobin A | 2 | 2008 | 4 | 0.090 |
Why?
|
| Perioperative Period | 1 | 2011 | 24 | 0.090 |
Why?
|
| Thermometers | 1 | 2011 | 13 | 0.090 |
Why?
|
| DNA, Complementary | 5 | 2003 | 251 | 0.090 |
Why?
|
| Blood-Brain Barrier | 1 | 1991 | 99 | 0.090 |
Why?
|
| Mastectomy | 2 | 2021 | 57 | 0.090 |
Why?
|
| Liposomes | 2 | 2014 | 107 | 0.090 |
Why?
|
| Carcinoma, Ductal | 1 | 2010 | 14 | 0.090 |
Why?
|
| Carcinoma, Lobular | 1 | 2010 | 20 | 0.090 |
Why?
|
| Endosonography | 2 | 2005 | 177 | 0.090 |
Why?
|
| History, 19th Century | 1 | 2010 | 95 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2010 | 3259 | 0.090 |
Why?
|
| Blood Coagulation | 1 | 2011 | 123 | 0.090 |
Why?
|
| Postoperative Complications | 3 | 1999 | 1615 | 0.090 |
Why?
|
| Tyrosine | 2 | 2001 | 196 | 0.090 |
Why?
|
| Carcinoma | 1 | 1992 | 215 | 0.090 |
Why?
|
| Leukopenia | 1 | 2010 | 23 | 0.090 |
Why?
|
| Gastrointestinal Tract | 1 | 2010 | 63 | 0.090 |
Why?
|
| Ischemic Attack, Transient | 1 | 1991 | 167 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 1070 | 0.090 |
Why?
|
| CD11 Antigens | 1 | 2009 | 2 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2010 | 127 | 0.090 |
Why?
|
| Receptors, Chemokine | 1 | 2010 | 26 | 0.090 |
Why?
|
| Proteins | 3 | 2019 | 474 | 0.090 |
Why?
|
| South Carolina | 3 | 2018 | 2752 | 0.090 |
Why?
|
| HIV Infections | 1 | 2018 | 791 | 0.090 |
Why?
|
| Propionates | 4 | 2003 | 21 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2010 | 248 | 0.090 |
Why?
|
| Mice, Nude | 3 | 2015 | 294 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2015 | 304 | 0.080 |
Why?
|
| Interferon Inducers | 1 | 2009 | 2 | 0.080 |
Why?
|
| Lymphopenia | 1 | 2009 | 12 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1992 | 300 | 0.080 |
Why?
|
| Quinoxalines | 4 | 2003 | 78 | 0.080 |
Why?
|
| Brain Ischemia | 2 | 1992 | 665 | 0.080 |
Why?
|
| Cell Line | 3 | 2005 | 1752 | 0.080 |
Why?
|
| Sequence Alignment | 5 | 2003 | 165 | 0.080 |
Why?
|
| Seroma | 1 | 2008 | 3 | 0.080 |
Why?
|
| Ligands | 1 | 2010 | 317 | 0.080 |
Why?
|
| beta 2-Microglobulin | 1 | 2008 | 15 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2009 | 714 | 0.080 |
Why?
|
| Catheterization | 1 | 2009 | 209 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 1991 | 320 | 0.080 |
Why?
|
| Combined Modality Therapy | 5 | 2014 | 951 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 332 | 0.080 |
Why?
|
| Transgenes | 1 | 2008 | 92 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2007 | 76 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2005 | 137 | 0.080 |
Why?
|
| Hemorrhage | 2 | 2004 | 328 | 0.080 |
Why?
|
| Cell Movement | 2 | 2008 | 630 | 0.080 |
Why?
|
| Stem Cells | 1 | 2009 | 248 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 114 | 0.080 |
Why?
|
| Mesothelioma | 1 | 2008 | 21 | 0.080 |
Why?
|
| MART-1 Antigen | 2 | 1997 | 10 | 0.080 |
Why?
|
| L-Selectin | 1 | 2007 | 28 | 0.070 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 248 | 0.070 |
Why?
|
| Neurons | 1 | 1993 | 881 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2010 | 1553 | 0.070 |
Why?
|
| Iridium Radioisotopes | 1 | 2007 | 11 | 0.070 |
Why?
|
| Antigens, Ly | 1 | 2007 | 14 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 2 | 2007 | 199 | 0.070 |
Why?
|
| Survival Rate | 3 | 2013 | 1056 | 0.070 |
Why?
|
| HLA-A2 Antigen | 3 | 2012 | 18 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1992 | 629 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2003 | 28 | 0.070 |
Why?
|
| Alum Compounds | 1 | 2006 | 2 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2008 | 231 | 0.070 |
Why?
|
| Immune System Diseases | 1 | 2006 | 12 | 0.070 |
Why?
|
| Egg Proteins | 2 | 2004 | 15 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2007 | 46 | 0.070 |
Why?
|
| Single-Chain Antibodies | 2 | 2019 | 15 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 94 | 0.070 |
Why?
|
| Reference Values | 2 | 2005 | 579 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 101 | 0.070 |
Why?
|
| Reference Standards | 2 | 2008 | 115 | 0.070 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2005 | 38 | 0.070 |
Why?
|
| Gene Expression | 4 | 2015 | 770 | 0.060 |
Why?
|
| Chemokines | 1 | 2006 | 119 | 0.060 |
Why?
|
| Plants | 2 | 1998 | 26 | 0.060 |
Why?
|
| Transfection | 3 | 2015 | 782 | 0.060 |
Why?
|
| Cyclohexanones | 2 | 2003 | 9 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2007 | 330 | 0.060 |
Why?
|
| Hypertension | 2 | 1991 | 1535 | 0.060 |
Why?
|
| Pancreatitis, Chronic | 1 | 2007 | 168 | 0.060 |
Why?
|
| Arabidopsis Proteins | 2 | 2003 | 13 | 0.060 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2015 | 40 | 0.060 |
Why?
|
| DNA, Neoplasm | 2 | 1996 | 95 | 0.060 |
Why?
|
| Interleukin-17 | 2 | 2015 | 62 | 0.060 |
Why?
|
| Barrett Esophagus | 1 | 2005 | 57 | 0.060 |
Why?
|
| Substrate Specificity | 5 | 2003 | 234 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2005 | 150 | 0.060 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2003 | 3 | 0.060 |
Why?
|
| Monocytes | 2 | 1996 | 210 | 0.060 |
Why?
|
| Uridine Diphosphate Glucose | 1 | 2003 | 19 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2004 | 47 | 0.060 |
Why?
|
| Chlorophenols | 1 | 2003 | 6 | 0.060 |
Why?
|
| Administration, Topical | 2 | 2004 | 111 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 191 | 0.060 |
Why?
|
| Poa | 1 | 2003 | 1 | 0.060 |
Why?
|
| Soybeans | 1 | 2003 | 11 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 1994 | 334 | 0.060 |
Why?
|
| Glycosyltransferases | 1 | 2003 | 13 | 0.060 |
Why?
|
| Genes, T-Cell Receptor alpha | 1 | 2003 | 3 | 0.050 |
Why?
|
| CD8 Antigens | 1 | 2003 | 25 | 0.050 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2003 | 5 | 0.050 |
Why?
|
| Signal Transduction | 4 | 2015 | 2689 | 0.050 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2003 | 24 | 0.050 |
Why?
|
| RNA | 1 | 2004 | 171 | 0.050 |
Why?
|
| Rats, Inbred WKY | 2 | 1993 | 48 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2004 | 159 | 0.050 |
Why?
|
| Drug Delivery Systems | 2 | 2015 | 236 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2005 | 682 | 0.050 |
Why?
|
| Macrophages | 1 | 2006 | 647 | 0.050 |
Why?
|
| Glutathione Peroxidase | 2 | 1999 | 39 | 0.050 |
Why?
|
| Glycoproteins | 2 | 2003 | 238 | 0.050 |
Why?
|
| Swine | 2 | 2004 | 672 | 0.050 |
Why?
|
| Gels | 3 | 2010 | 55 | 0.050 |
Why?
|
| Antidotes | 1 | 2002 | 21 | 0.050 |
Why?
|
| Phenols | 1 | 2002 | 73 | 0.050 |
Why?
|
| Computer Systems | 1 | 2001 | 42 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 33 | 0.050 |
Why?
|
| Delayed-Action Preparations | 2 | 2001 | 120 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 1293 | 0.050 |
Why?
|
| Environmental Pollutants | 1 | 2003 | 180 | 0.050 |
Why?
|
| Rats | 4 | 1993 | 5300 | 0.050 |
Why?
|
| Escherichia coli | 2 | 2000 | 368 | 0.050 |
Why?
|
| Waste Management | 1 | 2020 | 11 | 0.050 |
Why?
|
| Gene Silencing | 2 | 2015 | 137 | 0.050 |
Why?
|
| Dimerization | 4 | 2002 | 99 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2001 | 85 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2000 | 129 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2002 | 403 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1851 | 0.040 |
Why?
|
| Apolipoproteins | 1 | 1999 | 51 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 1999 | 30 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 467 | 0.040 |
Why?
|
| Pancreaticoduodenectomy | 1 | 1999 | 34 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1999 | 22 | 0.040 |
Why?
|
| B7-2 Antigen | 1 | 1999 | 23 | 0.040 |
Why?
|
| Acetylation | 1 | 1999 | 94 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2000 | 324 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 1999 | 81 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1999 | 42 | 0.040 |
Why?
|
| Postoperative Hemorrhage | 1 | 1999 | 69 | 0.040 |
Why?
|
| Inactivation, Metabolic | 3 | 2003 | 28 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 778 | 0.040 |
Why?
|
| Intestine, Small | 1 | 1999 | 89 | 0.040 |
Why?
|
| Plant Roots | 3 | 2003 | 22 | 0.040 |
Why?
|
| Th1 Cells | 1 | 1999 | 101 | 0.040 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1998 | 11 | 0.040 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1998 | 6 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 1998 | 12 | 0.040 |
Why?
|
| Keratins | 1 | 1998 | 48 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 652 | 0.040 |
Why?
|
| Antigens, CD | 1 | 1999 | 230 | 0.040 |
Why?
|
| Indoleacetic Acids | 1 | 1998 | 2 | 0.040 |
Why?
|
| Genes, MHC Class I | 1 | 2018 | 14 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 931 | 0.040 |
Why?
|
| Biological Products | 1 | 2019 | 78 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1997 | 95 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 376 | 0.040 |
Why?
|
| Biliary Tract Neoplasms | 1 | 1997 | 17 | 0.040 |
Why?
|
| Cholangiography | 1 | 1997 | 55 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 425 | 0.040 |
Why?
|
| Viral Load | 1 | 2018 | 127 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 1997 | 59 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1999 | 185 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 125 | 0.040 |
Why?
|
| Melanoma-Specific Antigens | 1 | 1996 | 3 | 0.040 |
Why?
|
| HLA-A Antigens | 1 | 1996 | 8 | 0.040 |
Why?
|
| Tumor Escape | 1 | 1996 | 37 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2016 | 659 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1999 | 597 | 0.030 |
Why?
|
| Alkenes | 1 | 2016 | 7 | 0.030 |
Why?
|
| HIV-1 | 1 | 2018 | 177 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 1996 | 80 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 70 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2016 | 77 | 0.030 |
Why?
|
| Epithelial Cell Adhesion Molecule | 2 | 2007 | 12 | 0.030 |
Why?
|
| Azides | 1 | 2016 | 56 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 504 | 0.030 |
Why?
|
| United States | 2 | 2013 | 7367 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1998 | 275 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2016 | 114 | 0.030 |
Why?
|
| Superoxides | 1 | 1996 | 70 | 0.030 |
Why?
|
| Phagocytosis | 1 | 1996 | 65 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 87 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 87 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2009 | 765 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2016 | 90 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 226 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 33 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2015 | 52 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 215 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 1997 | 247 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1995 | 71 | 0.030 |
Why?
|
| Immunoglobulin Constant Regions | 1 | 1994 | 12 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 104 | 0.030 |
Why?
|
| Mammography | 1 | 1997 | 310 | 0.030 |
Why?
|
| Perception | 1 | 2016 | 189 | 0.030 |
Why?
|
| Tetrazolium Salts | 2 | 1991 | 36 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 337 | 0.030 |
Why?
|
| Phenylephrine | 2 | 1991 | 61 | 0.030 |
Why?
|
| Rats, Inbred SHR | 2 | 1991 | 95 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 1998 | 1140 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 1994 | 26 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 1994 | 47 | 0.030 |
Why?
|
| Cerebral Arteries | 2 | 1991 | 50 | 0.030 |
Why?
|
| Capecitabine | 1 | 2014 | 11 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 21 | 0.030 |
Why?
|
| Patient Selection | 1 | 1998 | 592 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1994 | 94 | 0.030 |
Why?
|
| Poxviridae | 1 | 2013 | 13 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2014 | 89 | 0.030 |
Why?
|
| Platelet Count | 1 | 1994 | 100 | 0.030 |
Why?
|
| Lipids | 1 | 2015 | 298 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 130 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 507 | 0.030 |
Why?
|
| Necrosis | 1 | 1994 | 239 | 0.030 |
Why?
|
| Gene Expression Regulation, Plant | 2 | 2003 | 19 | 0.030 |
Why?
|
| Particle Size | 1 | 2014 | 201 | 0.030 |
Why?
|
| Decision Making | 1 | 1996 | 410 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 111 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 1996 | 1040 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2013 | 19 | 0.030 |
Why?
|
| Plant Shoots | 2 | 2003 | 6 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 111 | 0.030 |
Why?
|
| Species Specificity | 2 | 2003 | 303 | 0.030 |
Why?
|
| Flavonoids | 2 | 2003 | 109 | 0.030 |
Why?
|
| SEER Program | 1 | 2013 | 153 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2005 | 562 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 567 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2012 | 35 | 0.030 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2012 | 8 | 0.030 |
Why?
|
| Sarcoma, Synovial | 1 | 2012 | 11 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1996 | 1745 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 1992 | 29 | 0.030 |
Why?
|
| Depression, Chemical | 1 | 1992 | 29 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 63 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 36 | 0.030 |
Why?
|
| Prosencephalon | 1 | 1992 | 38 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 124 | 0.020 |
Why?
|
| Evans Blue | 1 | 1991 | 4 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2003 | 282 | 0.020 |
Why?
|
| Constriction | 1 | 1991 | 37 | 0.020 |
Why?
|
| Markov Chains | 1 | 2012 | 133 | 0.020 |
Why?
|
| Niacinamide | 1 | 1991 | 31 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1993 | 649 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 792 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2010 | 62 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 2 | 2003 | 208 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 2 | 2002 | 56 | 0.020 |
Why?
|
| Pancreas | 1 | 2011 | 225 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1992 | 205 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 1992 | 271 | 0.020 |
Why?
|
| Genes, Plant | 2 | 2000 | 15 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2012 | 307 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2006 | 2077 | 0.020 |
Why?
|
| Binding Sites | 2 | 2002 | 631 | 0.020 |
Why?
|
| Enzyme Induction | 2 | 2002 | 119 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2013 | 254 | 0.020 |
Why?
|
| Models, Molecular | 2 | 2002 | 546 | 0.020 |
Why?
|
| Molecular Weight | 2 | 2003 | 358 | 0.020 |
Why?
|
| Critical Care | 1 | 1992 | 263 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 125 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1997 | 2223 | 0.020 |
Why?
|
| Length of Stay | 1 | 1992 | 780 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 238 | 0.020 |
Why?
|
| Myelin and Lymphocyte-Associated Proteolipid Proteins | 1 | 2007 | 3 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 392 | 0.020 |
Why?
|
| Proteolipids | 1 | 2007 | 20 | 0.020 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2007 | 14 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2007 | 27 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 536 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 266 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2007 | 85 | 0.020 |
Why?
|
| Liver | 1 | 1992 | 1118 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2007 | 87 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 58 | 0.020 |
Why?
|
| G2 Phase | 1 | 2005 | 26 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 40 | 0.020 |
Why?
|
| Trefoil Factor-1 | 1 | 2005 | 2 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2005 | 36 | 0.020 |
Why?
|
| Dihydropyridines | 2 | 1996 | 13 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 97 | 0.020 |
Why?
|
| alpha Catenin | 1 | 2004 | 2 | 0.020 |
Why?
|
| Phenotype | 1 | 2008 | 947 | 0.020 |
Why?
|
| Fibrin Foam | 1 | 2004 | 1 | 0.020 |
Why?
|
| Hemophilia B | 1 | 2004 | 2 | 0.020 |
Why?
|
| Cellulose, Oxidized | 1 | 2004 | 3 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 174 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2004 | 17 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 1038 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 2004 | 22 | 0.010 |
Why?
|
| Paracrine Communication | 1 | 2004 | 31 | 0.010 |
Why?
|
| beta Catenin | 1 | 2004 | 73 | 0.010 |
Why?
|
| Wounds, Penetrating | 1 | 2004 | 45 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2004 | 87 | 0.010 |
Why?
|
| Aprotinin | 1 | 2004 | 55 | 0.010 |
Why?
|
| Chloroplasts | 2 | 1994 | 3 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2004 | 50 | 0.010 |
Why?
|
| Cadherins | 1 | 2004 | 93 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 160 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 194 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2003 | 36 | 0.010 |
Why?
|
| Thrombin | 1 | 2004 | 117 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 108 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 2003 | 34 | 0.010 |
Why?
|
| Rabbits | 1 | 2004 | 509 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2003 | 165 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2004 | 304 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 230 | 0.010 |
Why?
|
| Biotransformation | 1 | 2003 | 69 | 0.010 |
Why?
|
| Plant Leaves | 1 | 2003 | 49 | 0.010 |
Why?
|
| Acyltransferases | 1 | 2003 | 40 | 0.010 |
Why?
|
| Phenobarbital | 1 | 2003 | 25 | 0.010 |
Why?
|
| Oleic Acid | 2 | 1994 | 40 | 0.010 |
Why?
|
| Oleic Acids | 2 | 1994 | 40 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 237 | 0.010 |
Why?
|
| Glycosylation | 1 | 2003 | 185 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 700 | 0.010 |
Why?
|
| Biological Transport | 1 | 2003 | 210 | 0.010 |
Why?
|
| Mediastinum | 1 | 2003 | 39 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 254 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2003 | 189 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2003 | 202 | 0.010 |
Why?
|
| Phylogeny | 1 | 2003 | 197 | 0.010 |
Why?
|
| Protein Structure, Quaternary | 1 | 2001 | 31 | 0.010 |
Why?
|
| Homogentisic Acid | 1 | 2000 | 1 | 0.010 |
Why?
|
| Catalysis | 1 | 2001 | 123 | 0.010 |
Why?
|
| Serine | 1 | 2001 | 99 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2001 | 99 | 0.010 |
Why?
|
| Cysteine | 1 | 2001 | 112 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2001 | 204 | 0.010 |
Why?
|
| cis-trans-Isomerases | 1 | 2000 | 63 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2001 | 190 | 0.010 |
Why?
|
| Granisetron | 1 | 2000 | 1 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 954 | 0.010 |
Why?
|
| Life Tables | 1 | 2000 | 29 | 0.010 |
Why?
|
| Ondansetron | 1 | 2000 | 13 | 0.010 |
Why?
|
| Antiemetics | 1 | 2000 | 8 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 322 | 0.010 |
Why?
|
| Nausea | 1 | 2000 | 47 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2000 | 62 | 0.010 |
Why?
|
| Vomiting | 1 | 2000 | 56 | 0.010 |
Why?
|
| Apolipoproteins D | 1 | 1999 | 1 | 0.010 |
Why?
|
| Lung | 1 | 2005 | 849 | 0.010 |
Why?
|
| Income | 1 | 2001 | 167 | 0.010 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 1999 | 12 | 0.010 |
Why?
|
| Ampulla of Vater | 1 | 1999 | 34 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 150 | 0.010 |
Why?
|
| Cisplatin | 1 | 2000 | 192 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 981 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 1196 | 0.010 |
Why?
|
| Risk | 1 | 2000 | 563 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2001 | 254 | 0.010 |
Why?
|
| Lactoylglutathione Lyase | 1 | 1998 | 7 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1998 | 48 | 0.010 |
Why?
|
| Radiography | 1 | 1999 | 572 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1998 | 73 | 0.010 |
Why?
|
| Bile Ducts | 1 | 1997 | 59 | 0.010 |
Why?
|
| Pancreatic Ducts | 1 | 1997 | 76 | 0.010 |
Why?
|
| Clone Cells | 1 | 1997 | 67 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1998 | 152 | 0.010 |
Why?
|
| Pancreatitis | 1 | 1999 | 279 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1998 | 362 | 0.010 |
Why?
|
| Logistic Models | 1 | 2001 | 1420 | 0.010 |
Why?
|
| Peas | 1 | 1996 | 2 | 0.010 |
Why?
|
| Acyl Coenzyme A | 1 | 1996 | 6 | 0.010 |
Why?
|
| Citric Acid | 1 | 1996 | 16 | 0.010 |
Why?
|
| Blood Bactericidal Activity | 1 | 1996 | 2 | 0.010 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1996 | 7 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1996 | 8 | 0.010 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 1996 | 19 | 0.010 |
Why?
|
| Aspergillus fumigatus | 1 | 1996 | 27 | 0.010 |
Why?
|
| Candida albicans | 1 | 1996 | 39 | 0.010 |
Why?
|
| Mutation | 1 | 2001 | 1213 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1996 | 189 | 0.010 |
Why?
|
| NADPH Oxidases | 1 | 1996 | 80 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1995 | 8 | 0.010 |
Why?
|
| Comorbidity | 1 | 1999 | 1426 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 2324 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 1999 | 718 | 0.010 |
Why?
|
| Palmitic Acids | 1 | 1994 | 15 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 1996 | 175 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1999 | 1330 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1997 | 348 | 0.010 |
Why?
|
| Palmitic Acid | 1 | 1994 | 51 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 618 | 0.010 |
Why?
|
| Wound Healing | 1 | 1995 | 260 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2001 | 2800 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 8912 | 0.010 |
Why?
|
| Malonates | 1 | 1991 | 4 | 0.010 |
Why?
|
| Fatty Acid Synthases | 1 | 1991 | 6 | 0.010 |
Why?
|
| NADP | 1 | 1991 | 39 | 0.010 |
Why?
|
| Acetates | 1 | 1991 | 74 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1991 | 149 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1991 | 144 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1991 | 705 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1991 | 1451 | 0.000 |
Why?
|
| Brain | 1 | 1991 | 2176 | 0.000 |
Why?
|